Advertisement
Annals
Established in 1927 by the American College of Physicians
:
Advanced search
 


Cover Image   
box In this Issue
  arrow Articles
  arrow Improving Patient Care
  arrow Reviews
  arrow Editorials
  arrow Letters
  arrow Medical Writings: Book Notes
  arrow Ancillary Content
  arrow Summaries for Patients
  arrow PDF of Contents
box Services
  arrow Subscribe
  arrow One-time access
  arrow Activate online subscription
  arrow Access Personal Archive
 
box In this Issue
  arrow Articles
  arrow Improving Patient Care
  arrow Reviews
  arrow Editorials
  arrow Letters
  arrow Medical Writings: Book Notes
  arrow Ancillary Content
  arrow Summaries for Patients
  arrow PDF of Contents
box Services
  arrow Subscribe
  arrow One-time access
  arrow Activate online subscription
  arrow Access Personal Archive
 

TABLE OF CONTENTS

1 March 2005 Volume 142 Issue 5
< Previous Issue  |  Next Issue >
Clear

Articles Back

George Davey Smith, Yiscah Bracha, Kenneth H. Svendsen, James D. Neaton, Steven M. Haffner, Lewis H. Kuller for the Multiple Risk Factor Intervention Trial Research Group*

In previous trials of strategies to prevent type 2 diabetes, the participants had impaired glucose tolerance. This secondary analysis of the Multiple Risk Factor Intervention Trial (MRFIT) studied people with normal glucose tolerance. In nonsmokers, interventions to change diet and increase exercise reduced the risk for diabetes.

Abstract | Full Text | PDF | Summary for Patients

William H. Herman, Thomas J. Hoerger, Michael Brandle, Katherine Hicks, Stephen Sorensen, Ping Zhang, Richard F. Hamman, Ronald T. Ackermann, Michael M. Engelgau, Robert E. Ratner for the Diabetes Prevention Program Research Group*

This cost-effectiveness analysis estimates that the Diabetes Prevention Program's lifestyle intervention would cost society about $8800 per quality-adjusted life-year saved. The corresponding result for metformin was $29 900. The lifestyle intervention was cost-effective at any adult age; metformin was not cost-effective after age 65 years.

Abstract | Full Text | PDF | Summary for Patients | Technical Report

Brian J. McMahon, Dana L. Bruden, Kenneth M. Petersen, Lisa R. Bulkow, Alan J. Parkinson, Omana Nainan, Marina Khristova, Carolyn Zanis, Helen Peters, and Harold S. Margolis

The duration of protection afforded by hepatitis B vaccination is unknown. In this cohort of Alaska Natives who received vaccination against hepatitis, antibody levels decreased over a 15-year period, but breakthrough hepatitis B virus infection was very infrequent in all age groups.

Abstract | Full Text | PDF | Summary for Patients

Mark J. Sarnak, Tom Greene, Xuelei Wang, Gerald Beck, John W. Kusek, Allan J. Collins, and Andrew S. Levey

The optimal blood pressure to slow progression of chronic kidney disease is not known. In this report of long-term follow-up of patients with a moderately to severely decreased glomerular filtration rate in the Modification of Diet in Renal Disease Study, random assignment to a low target blood pressure slowed the progression of nondiabetic kidney disease.

Abstract | Full Text | PDF | Summary for Patients


Improving Patient Care Back

Tejal K. Gandhi

This article, part of the Quality Grand Rounds series, examines the case of a patient whose diagnosis of tuberculosis was substantially delayed because of systems problems, including poor continuity of care, failure to communicate test results and other clinical information, and several mismanaged handoffs. The article discusses strategies to ensure adequate communication of critical information and follow-up of test results.

Abstract | Full Text | PDF


Reviews Back

Fotini B. Karassa, Miltiadis I. Matsagas, Wolfgang A. Schmidt, and John P.A. Ioannidis

This meta-analysis shows a sensitivity and specificity of 86% when the halo sign or occlusion or stenosis is present. The post-test probability is low if none of these findings are present and the pretest probability is low. Ultrasonography can be useful for giant-cell arteritis if interpreted in light of the patient's clinical presentation.

Abstract | Full Text | PDF | Summary for Patients

Simon Sanderson, Jon Emery, Trevor Baglin, and Ann-Louise Kinmonth

Aspirin is an important drug for the secondary prevention of cardiovascular disease, but recurrent vascular events are common even when patients take aspirin. This paper reviews the concept of aspirin resistance, its measurement, and its clinical consequences for patients prescribed aspirin to prevent recurrences of cardiovascular disease.

Abstract | Full Text | PDF


Editorials Back

Jaakko Tuomilehto

Many large public health problems and epidemics have been overcome by acting on much less evidence than we have for preventing type 2 diabetes. Therefore, we should act as if vigorous measures could control the emerging epidemic of diabetes, even though we may not eradicate this disease in those with a strong genetic background.

Full Text | PDF

Ding-Shinn Chen

McMahon and colleagues' study in this issue reveals that serum levels of antibodies to hepatitis B surface antigen declined faster in persons who were immunized at 0.5 to 4 years of age. However, unless continued surveillance shows clinically significant rates of infection in adolescents or adults who were vaccinated as children, booster vaccinations will be wasteful.

Full Text | PDF


Letters Back

Care Management for Heart Failure

    Robert F. DeBusk, Daniel J. Cher, and Helena C. Kraemer—RESPONSE

    Full Text | PDF

Angiotensin-Converting Enzyme Inhibitors and Angiotensin-Receptor Blockers in Chronic Heart Failure

    Mark B. McClellan, Jerod M. Loeb, Carolyn M. Clancy, Gary S. Francis, Alice K. Jacobs, Kenneth W. Kizer, Margaret E. O'Kane, and Michael J. Wolk

    Full Text | PDF

    Victor C. Lee, David C. Rhew, and Glenn D. Braunstein—RESPONSE

    Full Text | PDF

Demarcated Truncal Jaundice: A Sign of Retroperitoneal Bile Leakage

The International Campaign to Revitalise Academic Medicine

Correction: Angiotensin-Receptor Blockers in Chronic Heart Failure and High-Risk Acute Myocardial Infarction



Medical Writings: Book Notes Back

Pierce Gardner

Full Text | PDF

Mark D. Hannis

Full Text | PDF


Ancillary Content Back

Full Text


Summaries for Patients Back

Full Text | PDF

Full Text | PDF

Full Text | PDF

Full Text | PDF

Full Text | PDF



 Home | Current Issue | Past Issues | Audio/Video | CME | Collections | In the Clinic | Mobile | Subscribe | Tools | Help | ACP Online 

Copyright © 2008 by the American College of Physicians.